Appointment strengthens senior team in preparation for EU regulatory approval and commercial launch of Mcm5-ELISA test
Sunderland, UK, 13 July 2016: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ELISA-based urine test for cancer, today announced the appointment of Louise Flintoft to the post of Product Manager. Louise’s appointment serves to strengthen Arquer’s commercial team in preparation for EU regulatory approval and commercial launch of its Mcm5-ELISA test. Louise will take responsibility for all aspects of product marketing, commercial management and distribution, as well as being a key contributor to future product development and commercialisation.
Louise brings a highly complementary set of commercial and technical skills to the group. She has over 10 years’ sales and marketing experience in the biotech and companion diagnostic industries, and has led global product marketing and launch campaigns, across Europe and the US. In-house experience includes roles with Leica Biosystems, Vision BioSystems and Novacastra Laboratories. Louise completed a Batchelor’s Degree with Honours in Physiology at the University of Newcastle.
Commenting on the appointment, Dr Ian Campbell, CEO of Arquer Diagnostics, said: "I am delighted to welcome Louise to Arquer. Her sales and marketing experience and expertise, specifically in the area of cancer diagnostics, are an ideal fit for the team. I look forward to working with her as the Company continues to expand its global distribution network and prepares for EU regulatory submission and market launch of our Mcm5-ELISA diagnostic test.”
Bladder cancer is currently diagnosed by cystoscopy, which is expensive and uncomfortable for patients. Arquer’s Mcm5-ELISA is a simple, non-invasive test, which detects the presence of minichromosome maintenance complex component 5 (Mcm5) protein in urine. Arquer recently announced ethical approval for the largest privately funded bladder cancer study in the UK and achieved a key commercial milestone with the announcement of the Companies first manufacturing and supply agreement in February this year.
Sunderland, UK, 13 July 2016: Arquer Diagnostics Ltd (Arquer), a diagnostic company which has developed a high sensitivity, high specificity, ELISA-based urine test for cancer, today announced the appointment of Louise Flintoft to the post of Product Manager. Louise’s appointment serves to strengthen Arquer’s commercial team in preparation for EU regulatory approval and commercial launch of its Mcm5-ELISA test. Louise will take responsibility for all aspects of product marketing, commercial management and distribution, as well as being a key contributor to future product development and commercialisation.
Louise brings a highly complementary set of commercial and technical skills to the group. She has over 10 years’ sales and marketing experience in the biotech and companion diagnostic industries, and has led global product marketing and launch campaigns, across Europe and the US. In-house experience includes roles with Leica Biosystems, Vision BioSystems and Novacastra Laboratories. Louise completed a Batchelor’s Degree with Honours in Physiology at the University of Newcastle.
Commenting on the appointment, Dr Ian Campbell, CEO of Arquer Diagnostics, said: "I am delighted to welcome Louise to Arquer. Her sales and marketing experience and expertise, specifically in the area of cancer diagnostics, are an ideal fit for the team. I look forward to working with her as the Company continues to expand its global distribution network and prepares for EU regulatory submission and market launch of our Mcm5-ELISA diagnostic test.”
Bladder cancer is currently diagnosed by cystoscopy, which is expensive and uncomfortable for patients. Arquer’s Mcm5-ELISA is a simple, non-invasive test, which detects the presence of minichromosome maintenance complex component 5 (Mcm5) protein in urine. Arquer recently announced ethical approval for the largest privately funded bladder cancer study in the UK and achieved a key commercial milestone with the announcement of the Companies first manufacturing and supply agreement in February this year.
